Chunmeng Wang

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

Chunmeng Wang, Zhiqiang Wu, Yao Wang et al. · Clinical Cancer Research · 2016 · 323 citations

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia

Hanren Dai, Zhiqiang Wu, Hejin Jia et al. · Journal of Hematology & Oncology · 2020 · 312 citations · Full text

Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma

Chuan Tong, Yang Liu, Xingyu Ji et al. · Blood · 2020 · 272 citations · Full text

Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma

Jing Nie, Chunmeng Wang, Yang Liu et al. · Journal of Clinical Oncology · 2019 · 214 citations · Full text

Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia

Hanren Dai, Wenying Zhang, Xiaolei Li et al. · OncoImmunology · 2015 · 164 citations · Full text